AR091967A1 - Articulo de fabricacion que comprende aflibercept o 2iv-aflibercept - Google Patents
Articulo de fabricacion que comprende aflibercept o 2iv-afliberceptInfo
- Publication number
- AR091967A1 AR091967A1 ARP130102744A ARP130102744A AR091967A1 AR 091967 A1 AR091967 A1 AR 091967A1 AR P130102744 A ARP130102744 A AR P130102744A AR P130102744 A ARP130102744 A AR P130102744A AR 091967 A1 AR091967 A1 AR 091967A1
- Authority
- AR
- Argentina
- Prior art keywords
- biosimilar
- polypeptide
- patients
- interrupted
- seq
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D85/00—Containers, packaging elements or packages, specially adapted for particular articles or materials
- B65D85/70—Containers, packaging elements or packages, specially adapted for particular articles or materials for materials not otherwise provided for
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mechanical Engineering (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Wrappers (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicación 1: Un artículo de fabricación que comprende: a) un material de envasado, b) un polipéptido de SEQ ID Nº 1, o un biosimilar de éste, y c) una etiqueta o prospecto contenido en dicho envase, comprendiendo dicha etiqueta una declaración impresa que informa a un usuario potencial que: el polipéptido, o biosimilar de éste, no debe administrarse a pacientes con una hemorragia grave, y/o la terapia debe interrumpirse en pacientes que experimentan perforación gastrointestinal, y/o la terapia debe interrumpirse en pacientes con cicatrización de heridas comprometida. Reivindicación 10: Un método para promover el uso de un polipéptido de SEQ ID Nº 1, o un biosimilar de éste, comprendiendo el método la etapa de transmitir en un recipiente al menos un mensaje seleccionado del grupo que consiste en: a) el polipéptido, o biosimilar de éste, no debe administrarse a pacientes con una hemorragia grave, y/o b) el polipéptido, o biosimilar de éste, debe interrumpirse en pacientes que experimentan perforación gastrointestinal, y/o c) el polipéptido, o biosimilar de éste, debe interrumpirse en pacientes con cicatrización de heridas comprometida. Reivindicación 11: Un método para tratar cáncer o síntomas del cáncer en un paciente que lo necesita, comprendiendo dicho método administrar a dicho paciente cantidades terapéuticamente eficaces de un polipéptido de SEQ ID Nº 1, o biosimilar de éste, en el que: a) el polipéptido, o biosimilar de éste, no debe administrarse a pacientes con una hemorragia grave, y/o b) el polipéptido, o biosimilar de éste, debe interrumpirse en pacientes que experimentan perforación gastrointestinal, y/o c) el polipéptido, o biosimilar de éste, debe interrumpirse en pacientes con cicatrización de heridas comprometida. Reivindicación 12: Un método para tratar Cáncer Colorrectal (CRC) o síntomas de Cáncer Colorrectal (CRC) en un paciente que lo necesita, comprendiendo dicho método administrar a dicho paciente cantidades terapéuticamente eficaces de un polipéptido de SEQ ID Nº 1, o biosimilar de éste, ácido folínico, 5-fluorouracilo (5-FU) e irinotecán en el que: a) el polipéptido, o biosimilar de éste, no debe administrarse a pacientes con una hemorragia grave, y/o b) el polipéptido, o biosimilar de éste, debe interrumpirse en pacientes que experimentan perforación gastrointestinal, y/o c) el polipéptido, o biosimilar de éste, debe interrumpirse en pacientes con cicatrización de heridas comprometida. Reivindicación 31: Polipéptido de SEQ ID Nº 1, o biosimilar de éste, para uso en el tratamiento de pacientes con cáncer o síntomas de cáncer en el que: a) el polipéptido, o biosimilar de éste, no debe administrarse a pacientes con una hemorragia grave, y/o b) el polipéptido, o biosimilar de éste, debe interrumpirse en pacientes que experimentan perforación gastrointestinal, y/o c) el polipéptido, o biosimilar de éste, debe interrumpirse en pacientes con cicatrización de heridas comprometida. Reivindicación 33: Composición que comprende cantidades terapéuticamente eficaces de un polipéptido de SEQ ID Nº 1, o biosimilar de éste, en combinación con ácido folínico, 5-fluorouracilo (5-FU) e irinocetán y que comprende un vehículo farmacéuticamente aceptable para uso en el tratamiento de pacientes con Cáncer Colorrectal (CRC) o síntomas de Cáncer Colorrectal (CRC) en el que: a) el polipéptido, o biosimilar de éste, no debe administrarse a pacientes con una hemorragia grave, y/o b) el polipéptido, o biosimilar de éste, debe interrumpirse en pacientes que experimentan perforación gastrointestinal, y/o c) el polipéptido, o biosimilar de éste, debe interrumpirse en pacientes con cicatrización de heridas comprometida.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261678983P | 2012-08-02 | 2012-08-02 | |
| US201261679490P | 2012-08-03 | 2012-08-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR091967A1 true AR091967A1 (es) | 2015-03-11 |
Family
ID=48917540
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130102744A AR091967A1 (es) | 2012-08-02 | 2013-08-02 | Articulo de fabricacion que comprende aflibercept o 2iv-aflibercept |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20150216795A1 (es) |
| EP (1) | EP2879694A1 (es) |
| JP (1) | JP2015526430A (es) |
| KR (1) | KR20150038297A (es) |
| CN (1) | CN104853763A (es) |
| AR (1) | AR091967A1 (es) |
| AU (1) | AU2013298521A1 (es) |
| CA (1) | CA2888281A1 (es) |
| EA (1) | EA201590305A1 (es) |
| HK (1) | HK1206628A1 (es) |
| IL (1) | IL236931A0 (es) |
| MX (1) | MX2015001550A (es) |
| SG (1) | SG11201500480TA (es) |
| TW (1) | TW201408316A (es) |
| UY (1) | UY34962A (es) |
| WO (1) | WO2014020160A1 (es) |
| ZA (1) | ZA201500485B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3283B1 (ar) | 2011-04-26 | 2018-09-16 | Sanofi Sa | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) |
| AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| HUE043951T2 (hu) | 2014-07-18 | 2019-09-30 | Sanofi Sa | Eljárás rákgyanús beteg aflibercepttel történõ kezelése kimenetének elõrejelzésére |
| CN107922095A (zh) | 2015-06-17 | 2018-04-17 | 诺维信公司 | 容器 |
| TWI797060B (zh) | 2015-08-04 | 2023-04-01 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
| KR101936049B1 (ko) * | 2015-10-15 | 2019-01-08 | (주)알테오젠 | IgG Fc 도메인을 가지는 융합 단백질의 생산방법 |
| KR20180104635A (ko) | 2015-12-30 | 2018-09-21 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| MX2018009112A (es) * | 2016-01-25 | 2018-08-28 | Sanofi Sa | Metodo para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cancer mediante la medicion del nivel de un biomarcador plasmatico. |
| CA3067847A1 (en) * | 2017-07-06 | 2019-01-10 | Regeneron Pharmaceuticals, Inc. | Cell culture process for making a glycoprotein |
| CN109929027B (zh) * | 2017-12-15 | 2020-10-09 | 山东博安生物技术有限公司 | 采用线性洗脱步骤的重组融合蛋白纯化方法 |
| CN109929038B (zh) * | 2017-12-15 | 2020-10-09 | 山东博安生物技术有限公司 | Vegf捕获剂融合蛋白的纯化方法 |
| EP3863657A4 (en) * | 2018-10-12 | 2022-07-20 | Trican Biotechnology Co., Ltd | BIFUNCTIONAL FUSION PROTEINS AND USES THEREOF |
| CA3127228A1 (en) * | 2019-01-30 | 2020-08-06 | Amgen Inc. | Aflibercept attributes and methods of characterizing and modifying thereof |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| SG11202110955VA (en) | 2019-12-06 | 2021-10-28 | Regeneron Pharma | Anti-vegf protein compositions and methods for producing the same |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2586459T1 (sl) * | 2005-03-25 | 2017-10-30 | Regeneron Pharmaceuticals, Inc. | Formulacije antagonistov VEGF |
| JO3283B1 (ar) * | 2011-04-26 | 2018-09-16 | Sanofi Sa | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) |
-
2013
- 2013-08-02 MX MX2015001550A patent/MX2015001550A/es unknown
- 2013-08-02 AR ARP130102744A patent/AR091967A1/es unknown
- 2013-08-02 JP JP2015524804A patent/JP2015526430A/ja active Pending
- 2013-08-02 AU AU2013298521A patent/AU2013298521A1/en not_active Abandoned
- 2013-08-02 UY UY0001034962A patent/UY34962A/es not_active Application Discontinuation
- 2013-08-02 KR KR20157004740A patent/KR20150038297A/ko not_active Application Discontinuation
- 2013-08-02 WO PCT/EP2013/066299 patent/WO2014020160A1/en active Application Filing
- 2013-08-02 SG SG11201500480TA patent/SG11201500480TA/en unknown
- 2013-08-02 EA EA201590305A patent/EA201590305A1/ru unknown
- 2013-08-02 EP EP13745404.7A patent/EP2879694A1/en not_active Ceased
- 2013-08-02 CN CN201380051246.5A patent/CN104853763A/zh active Pending
- 2013-08-02 CA CA 2888281 patent/CA2888281A1/en not_active Abandoned
- 2013-08-02 TW TW102127862A patent/TW201408316A/zh unknown
-
2015
- 2015-01-22 ZA ZA2015/00485A patent/ZA201500485B/en unknown
- 2015-01-26 IL IL236931A patent/IL236931A0/en unknown
- 2015-02-02 US US14/611,561 patent/US20150216795A1/en not_active Abandoned
- 2015-07-30 HK HK15107312.9A patent/HK1206628A1/xx unknown
-
2017
- 2017-01-18 US US15/409,377 patent/US20180078496A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014020160A1 (en) | 2014-02-06 |
| MX2015001550A (es) | 2015-05-11 |
| US20150216795A1 (en) | 2015-08-06 |
| IL236931A0 (en) | 2015-03-31 |
| EP2879694A1 (en) | 2015-06-10 |
| KR20150038297A (ko) | 2015-04-08 |
| SG11201500480TA (en) | 2015-02-27 |
| TW201408316A (zh) | 2014-03-01 |
| JP2015526430A (ja) | 2015-09-10 |
| US20180078496A1 (en) | 2018-03-22 |
| AU2013298521A1 (en) | 2015-02-26 |
| HK1206628A1 (en) | 2016-01-15 |
| CN104853763A (zh) | 2015-08-19 |
| EA201590305A1 (ru) | 2015-06-30 |
| ZA201500485B (en) | 2017-07-26 |
| CA2888281A1 (en) | 2014-02-06 |
| UY34962A (es) | 2014-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR091967A1 (es) | Articulo de fabricacion que comprende aflibercept o 2iv-aflibercept | |
| AR068302A1 (es) | Peptidos para vacunas para canceres que expresan antigenos asociados con tumores | |
| CY1119435T1 (el) | Σκευασμα για αντισωμα εναντι- αλφα4βητα7 | |
| NZ707377A (en) | Combination therapy methods for treating proliferative diseases | |
| WO2016086088A3 (en) | Wound healing through sirt1 overexpression | |
| BR112014021101A2 (pt) | Anticorpo, composição farmacêutica, droga de combinação, dna e método de tratamento e/ou prevenção de câncer, uso de um anticorpo | |
| BR112014021102A2 (pt) | Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo | |
| PH12015502042A1 (en) | Use of linagliptin in cardio-and renoprotective antidiabetic therapy | |
| CY1122483T1 (el) | Λυοφιλοποιημενες παρασκευες μελφαλανης φλουφεναμιδης | |
| RU2017101705A (ru) | Фармацевтическая композиция, предназначенная для применения для предупреждения и/или лечения заболевания, которое развивается или прогрессирует вследствие снижения или утраты активности фактора свертывания крови viii и/или активированного фактора свертывания крови viii | |
| NZ608502A (en) | Polypeptides that bind to human complement component c5 | |
| BR112015025464A2 (pt) | coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico | |
| MX2020000083A (es) | Factor de von willebrand recombinante ( rvwf ) y factor viii recombinante ( rfviii ) para usarse en un metodo para tratar la enfermedad de von willebrand. | |
| NZ705743A (en) | Compositions and methods for treating cutaneous scarring | |
| MX2016008362A (es) | Combinaciones farmaceuticas. | |
| AR086051A1 (es) | Metodo para tratar el cancer colorrectal, composicion que comprende aflibercept, acido folinico, 5-fluorouracilo (5-fu) e irinotecano (folfiri), articulo manufacturado, kit | |
| AR093479A1 (es) | Polipeptidos para el transporte de barrera hematoencefalica | |
| AR097619A1 (es) | Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris | |
| BR112014029954A2 (pt) | tratamento de tumores sólidos usando coenzima q10 | |
| BR112012013139A2 (pt) | oligopeptídeos imp-3 e vacinas incluindo os mesmos | |
| IN2014DN06920A (es) | ||
| BR112015000183A2 (pt) | proteínas de superfície específicas de variante (vsp) de protozoário como carreadores para entrega de fármaco oral | |
| UY36202A (es) | Composición farmacéutica que comprende hemoglobina recombinante o un agente terapéutico basado en subunidades para el tratamiento de cáncer | |
| CO7101247A2 (es) | Formulaciones de ácido poliinosínico-policitidílico (poli(i:c)) para el tratamiento de infecciones de las vías respiratorias altas | |
| BR112013033544A2 (pt) | dosagem e administração de anticorpos anti-erbb3 em combinação com paclitaxel para tratamento de cânceres ginecológicos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |